Table 3.

The comparison of the degree of the association between ES-SCZ and functioning across groups.

	GAF symptoms						GAF disabilities
	Siblings			Patients			Siblings			Patients
	Coefficient	95% CI	p-value	Coefficient	95% CI	p-value	Coefficient	95% CI	p-value	Coefficient	95% CI	p-value
Controlsa	1.50	0.25; 2.75	0.019	0.03	−1.22; 1.28	0.968	1.26	0.19; 2.33	0.021	0.32	−0.74; 1.39	0.552
Siblingsa	–	–	–	−1.47	−2.72; −0.23	0.020	–	–	–	−0.94	−2.17; 0.29	0.136
Controlsb	1.39	0.04; 2.75	0.043	−0.27	−1.64; 1.09	0.694	1.33	0.08; 2.57	0.037	−0.35	−1.57; 0.87	0.572
Siblingsb	–	–	–	−1.67	−3.14; −0.19	0.027	–	–	–	−1.68	−3.18; −0.17	0.029
Controlsc	1.29	−0.24; 2.81	0.097	−0.06	−1.56; 1.44	0.935	1.34	0.04; 2.64	0.044	0.13	−1.12; 1.38	0.838
Siblingsc	–	–	–	−1.35	−2.92; 0.22	0.092	–	–	–	−1.21	−2.81; 0.39	0.139

Notes: Comparisons between controls versus siblings, siblings versus patients, and controls versus patients.

Abbreviations: CI, confidence interval; ES-SCZ, exposome score for schizophrenia; GAF, Global Assessment of Functioning; PRS-SCZ, polygenic risk score for schizophrenia.

^aResults of the models adjusted for PRS-SCZ from the imputed dataset.

^bResults of the models from the unimputed dataset.

^cResults of the models adjusted for PRS-SCZ from the unimputed dataset.